Research Awards — Jan. 8-14, 2011
Ariizumi, Kiyoshi, NIH, DC-HIL in Cutaneous Immunity, $356,625; Banerjee, Subhash, Univ. of Toledo/NIH, CORAL - Cardiovascular Outcomes in Renal Atherosclerotic Lesions, $795; Bowens, Cindy, Univ. of Pennsylvania/NIH, Sedation Management in Pediatric Patients with Acute Respiratory Failure, $241,600; Burgess, Shawn, Duke Univ. Med. Ctr./NIH, Development of Novel Therapies for NIDDM: NMR-Based Flux Analysis; Core C, $109,811; Cannon-McCullough, Carolyn, Washington Univ. in St. Louis/NIH, Integrated Nanosystems for Diagnosis and Therapy, $221,136; Collins, Robert, National Marrow Donor Program/NIH, Blood and Marrow Transplant Clinical Trials Network, $2,800; Dobbie, Alison, HRSA, Expanded Training in Community Service Learning for Family Medicine Residents, $46,872; Drazner, Mark, Duke Univ. Med. Ctr./NIH, STICH-Surgical Treatment of Ischemic Heart Failure, $550; Fitzgerald, John, Duke Univ. Med. Ctr./NIH, IPFNET: Idiopathic Pulmonary Fibrosis Clinical Research Network, $19,782.
Freeman, Anne, Univ. of Calif., San Francisco/NIH, Community-Level HIV Prevention Intervention for Young Black Men - Extension Supplement, $99,180; Friedberg, Errol, NIH, Mouse Models of DNA Repair - Defective Human Diseases, $308,452; Frohman, Elliot, Univ. of Pennsylvania/NIH, Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MS - ARRA Stimulus Funding, $182,167; Girard, Luc, Duke Univ. Med. Ctr./NIH, Molecular Signatures of Lung Cancer, $47,332; Glazer, Craig, Duke Clinical Research Inst./NIH, IPF-ACE: Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis, $4,478; Greene, Robert, NIH , Dopamine Modulation of NMDA Receptor Synaptic Responses, $286,133; Hall, Christiana, Univ. of Cincinnati/NIH, Spot Sign for Predicting and Treating ICH Growth (STOP-IT) Study, $18,440; Hansen, Eric, NIH , Surface Proteins of Moraxella Catarrhalis, $314,746; He, Yu-Guang, Emmes Corp./NIH, Age-Related Eye Disease Study 2 (AREDS2), $3,078.
Holper, Elizabeth, Univ. of Toledo/NIH, CORAL - Cardiovascular Outcomes in Renal Atherosclerotic Lesions, $4,205; Huang, Chou-Long (M. Wolf, Fellow), Cincinnati Children’s Hospital Med. Ctr./NIH, Regulation of Na+ Homeostasis and Blood Pressure by WNK Kinases, $85,273; Idris, Ahamed, Univ. of Washington/NIH, Resuscitation Outcomes Consortium Regional Clinical Center - ROC Protocols; #692487, $60,000; Jain, Mamta, Fred Hutchinson Cancer Research Ctr./NIH, FHCRC HVTN 505 Protocol Site Expansion, $630,000; Johnson, Mark, Univ. of North Carolina at Chapel Hill/NIH, Carotid Occlusion Surgery Study (COSS), $9,924; Kennard, Beth, UT Dallas/NIH, Neuroimaging Biomarkers of Outcome for Diffuse Axonal Injury, $9,750; Khera, Amit, Yale Univ./NIH, Young Women with Acute Myocardial Infarction (VIRGO), $1,600; Lin, Rueyling, NIH , Transcriptional Regulation by Wnt Effector POP-1, $295,999; Mahony, Lynn, New England Research Inst./NIH, Pediatric Heart Disease Clinical Research Network, $70,642.
Markham, David, Univ. of Pittsburgh/NIH, Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy - ARRA Stimulus Funding, $10,250; McClung, Colleen, NIH , Role of Circadian Clock in Development and Treatment of Mood Disorders, $353,250; McKnight, Steven, Mount Sinai School of Medicine/NIH, Neural Substrates of Appetitive Behavior in Mood and Motivation - Project IV, $108,252; Mendelson, Carole, NIH , Mechanisms in the Regulation of SP-A Gene Expression, $444,063; Miller, David, Gynecologic Oncology Group/NIH, Gynecologic Oncology Group Studies, $69,904; Miller, David, Washington Univ. in St. Louis/NIH, Methylation Markers for Prognosis in Endometrioid Endometrial Cancers, $9,924; Otwinowski, Zbyszek, Northwestern Univ./NIH, Center for Structural Genomics of Infectious Diseases, $89,081; Peng, Fangyu, Johns Hopkins Univ./NIH, Molecular Physiology and Biochemistry of Wilson's Disease - ARRA Stimulus Funding, $61,401.
Powell, Craig, NIH , Neuroligin Function in vivo: Implications for Autism and Mental Retardation, $353,250; Raskin, Philip, Joslin Diabetes Ctr./NIH, Targeting Inflammation Using SALsalate for Type 2 Diabetes (TINSAL-T2D), $7,275; Richards, Benjamin, UT Health Science Ctr. at Houston/NIH, Genetic Studies of Clubfoot (ITEV), $24,186; Rogers, Zora, New England Research Inst./NIH, Thalassemia Clinical Research Network - Oral Sildenafil Pilot, $900; Rosen, Michael, NIH , Structural Study of GTPase Regulators and Effectors, $267,817; Scheuermann, Richard, Northrop Grumman Corp./NIH, Bioinformatics Integration Support Contract (BISC) - Phase II, $908,878; Skinner, Celette, Indiana Univ. Med. Ctr./NIH, Promoting Breast Cancer Screening via Computer vs. Phone, $39,268; Wakeland, Edward, Oklahoma Medical Research Foundation/NIH, Candidate Causal Variants in Systemic Lupus Erythematosus - ARRA Stimulus Grand Opps, $926,008.
Weakley, David, Jaeb Ctr. For Health/NIH, Pediatric Eye Disease Investigator Group: Amblyopia Treatment Study, $780; Winick, Naomi, National Childhood Cancer Foundation/NIH, COG Chair Grant PCR; #1233, $10,000; Winick, Naomi, National Childhood Cancer Foundation/NIH, COG Phase 1 Pilot Consortium PCR; #1021, $8,500; Wright, Woodring, NIH , Manipulating Telomerase Alternative Splicing for Cancer Therapy, $328,888; Yanagisawa, Hiromi, NIH, Loss of Matrix Regulation and Aortic Aneurysm Development in Vivo, $370,485.
Eisch, Amelia, NARSAD, Adult Neurogenesis and Stress-Induced Social Avoidance, $50,000; Monteggia, Lisa, Rett Syndrome Research Foundation, Elucidation of Epigenetic Mechanisms in Rett Syndrome, $49,999; Patel, Ashish, Emory Univ./Crohn's & Colitis Foundation, Risk Stratification and Identification of Immunogenetic and Microbial Markers of Complicated Disease Course in Pediatric Crohn's Disease, $62,600; Powell, Craig (M. Kouser, Fellow), Autism Speaks, Shank3 Mutant Characterization in Vivo, $28,000; Rosen, Michael (D. Jia, Fellow), Cancer Research Inst., Role of Lysine Methylation in Regulating Actin Cytoskeleton, $48,500; Scott, Daniel, Foundation for Surgical Fellowships, Foundation for Surgical Fellowship Grant, $62,500; Tu, Benjamin, David and Lucille Packard Foundation, Packard Fellowship 2010, $175,000; Ward Ober, E. Sally, Natl. Multiple Sclerosis Society, Targeting Autoreactive Antibodies for Therapy of Murine EAE, $165,192.
Industry Sponsored Awards, dollar amounts not available
Bowers, Daniel, Randomized Ph2 Study of Single-agent Erlotinib vs. Oral Etoposide in Pts with Recurrent or Refractory Pediatric Ependymoma; Brown, Spencer, Characterization of Facial Aging and Adipose Tissue and Connective Tissue of Thighs; Brown, Spencer, Quill SRS Synthetic Barbed Suture; Brown, Spencer, Test of CO-Filled Tissue Expanders in Rabbits; Brugarolas, James, Neoadjuvant RAD001 (Everolimus) for Advanced RCC Before Cytoreductive Nephrectomy, with Correlative Tumor Studies; Chin, Kelly, Multicenter, Double-Blind, Placebo-Controlled Ph3 Study to Demonstrate Efficacy and Safety of ACT-293987 in Pts with Pulmonary Arterial Hypertension; Chin, Kelly, Long-Term Single-Arm Open-Label Study to Assess Safety and Tolerability of ACT-293987 in Pts with Pulmonary Arterial Hypertension; Cruz, Ponciano, Studies of Skin Biology and Skin Disease and Colloquium; Daniels, James, Ph3b Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate Safety and Efficacy of Vernakalant Hydrochloride Injection in Pts with Recent Onset Symptomatic Atrial Fibrillation.
Joglar, Jose, Attain Success Clinical Investigation Plan; Modur, Pradeep, Multicenter, Open-Label Extn Trial to Assess Long-Term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-Onset Seizures; Petroll, Matthew, Assessment of Epithelial Toxicity Using Live/Dead Labeling; Roland, Peter, Electric-Acoustic Systems (EAS) Investigational Plan; Saha, Debabrata, Radiosensitization of NSCLC Cells with c-MET Amplification and EML4-ALK Fusion by PF-02341066; Thorpe, Philip, Vascular Targeting Agents for Treatment of Diseases; Turley, Stephen, Biliary Lipid Concentration Assay Study; Unger, Roger, GK Activation in Diabetes; Verma, Udit, Randomized, Double-Blind, PhII Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) vs. Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer; Verma, Udit, Randomized, Double-Blind, Placebo-Controlled PhIII Study of Regorafenib Plus BSC vs. Placebo Plus BSC in Pts with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy; Yopp, Adam, PhI/II Study of Bavituximab and Sorafenib in Pts with Advanced Hepatocellular Carcinoma.
Week of Jan. 8-14, 2011 /